Efficacy and tolerability of vildagliptin monotherapy in drug-naïve patients with type 2 diabetes
Authors:
- F. Xavier Pi-SunyerFPF. Xavier Pi-Sunyer
- Anja SchweizerASAnja Schweizer
- David MillsDMDavid Mills
- Sylvie DejagerSDSylvie Dejager
- 1 April 2007
- journal article
- research article
- Published by Elsevier in Diabetes Research and Clinical Practice
- Vol. 76 (1) , 132-138
Abstract
No abstract availableKeywords
This publication has 7 references indexed in Scilit:
- Twelve-week Monotherapy with the DPP-4 Inhibitor Vildagliptin Improves Glycemic Control in Subjects with Type 2 DiabetesHormone and Metabolic Research, 2006
- Improved glycaemic control with dipeptidyl peptidase‐4 inhibition in patients with type 2 diabetes: vildagliptin (LAF237) dose responseDiabetes, Obesity and Metabolism, 2005
- Vildagliptin, a Dipeptidyl Peptidase-IV Inhibitor, Improves Model-Assessed β-Cell Function in Patients with Type 2 DiabetesThe Journal of Clinical Endocrinology & Metabolism, 2005
- Glucagon-like peptide-1 mediates the therapeutic actions of DPP-IV inhibitorsDiabetologia, 2005
- Inhibition of Dipeptidyl Peptidase-4 Reduces Glycemia, Sustains Insulin Levels, and Reduces Glucagon Levels in Type 2 DiabetesThe Journal of Clinical Endocrinology & Metabolism, 2004
- Effects of Glucagon-Like Peptide 1 on Counterregulatory Hormone Responses, Cognitive Functions, and Insulin Secretion during Hyperinsulinemic, Stepped Hypoglycemic Clamp Experiments in Healthy VolunteersThe Journal of Clinical Endocrinology & Metabolism, 2002
- GLUCAGON-LIKE PEPTIDE-1 7-36: A PHYSIOLOGICAL INCRETIN IN MANThe Lancet, 1987